Skip to main content
Equibles
STLN logo

STLN · Starling Oncology, Inc. · Metrics

Track STLN — free

Use STLN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research STLN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.35 +0.14 (+2.17%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Aug 6, 2026

The latest filing states the doubt was alleviated.

“the Company conducted an evaluation as to whether there were conditions and events, considered in the aggregate, which raised substantial doubt as to its ability to continue as a going concern within one year after the date of the issuance of such financial statements. The Company had cash and cash equivalents of $41,094 and an accumulated deficit of $283,700 at June 30, 2026, and a net loss of $12,281 and net cash provided by operations of $9,725 for the six months ended June 30, 2026. The Company has concluded that it will have sufficient liquidity to fund its operations for at least one year from the date these consolidated financial statements are issued.”
View the 10-Q filed Aug 6, 2026
Market Cap
$678.76M
Shares
101.92M
Volume · Oct 2 793.88K Avg daily vol (3M) 1.58M

STLN metrics

34 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.35
Market cap
$678.76M

Price action

20 metrics
Price change (1W)
-4.7%
Price change (30D)
+0.5%
Price change (3M)
+20.3%
Price change (6M)
+103.5%
Price change (YTD)
+78.4%
Price change (1Y)
+84.6%
Trailing year
Price change (5Y)
-36.0%
52-week high
$7.05
52-week low
$2.39
Change from 52-week high
-9.9%
Change from 52-week low
+166.2%
Annualized volatility
80.0%
Annualized volatility (3M)
79.7%
Beta
1.6
RSI (14D)
49.0
Price vs SMA 50
+3.9%
Price vs SMA 200
+44.1%
Avg volume (3M)
1.58M
Relative volume
0.5
Average dollar volume
$9.53M

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
101.92M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
—
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
—
Total assets
—
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
130
13F filer change QoQ
+5
Institutional ownership
46.4%

Short interest

3 metrics
Short interest
6.9%
Latest settlement · 7.4 days to cover
Days to cover
7.4d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.84M
Insider-sentiment score
82 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1799191 CUSIP 68236X100 13F (30d) 2 filings 2 filers Visit website Investor relations